These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 7991583)
21. Role of caspases in immunotoxin-induced apoptosis of cancer cells. Keppler-Hafkemeyer A; Brinkmann U; Pastan I Biochemistry; 1998 Dec; 37(48):16934-42. PubMed ID: 9836586 [TBL] [Abstract][Full Text] [Related]
22. Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. Kuan CT; Pai LH; Pastan I Clin Cancer Res; 1995 Dec; 1(12):1589-94. PubMed ID: 9815960 [TBL] [Abstract][Full Text] [Related]
23. A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2. Bera TK; Onda M; Brinkmann U; Pastan I J Mol Biol; 1998 Aug; 281(3):475-83. PubMed ID: 9698563 [TBL] [Abstract][Full Text] [Related]
24. A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of Pseudomonas exotoxin. Brinkmann U; Gallo M; Brinkmann E; Kunwar S; Pastan I Proc Natl Acad Sci U S A; 1993 Jan; 90(2):547-51. PubMed ID: 8421689 [TBL] [Abstract][Full Text] [Related]
25. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Kreitman RJ; Wang QC; FitzGerald DJ; Pastan I Int J Cancer; 1999 Mar; 81(1):148-55. PubMed ID: 10077166 [TBL] [Abstract][Full Text] [Related]
26. Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins. Hexham JM; Dudas D; Hugo R; Thompson J; King V; Dowling C; Neville DM; Digan ME; Lake P Mol Immunol; 2001 Sep; 38(5):397-408. PubMed ID: 11684296 [TBL] [Abstract][Full Text] [Related]
27. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys. Pai LH; Batra JK; FitzGerald DJ; Willingham MC; Pastan I Cancer Res; 1992 Jun; 52(11):3189-93. PubMed ID: 1591729 [TBL] [Abstract][Full Text] [Related]
28. Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins. Roscoe DM; Pai LH; Pastan I Eur J Immunol; 1997 Jun; 27(6):1459-68. PubMed ID: 9209499 [TBL] [Abstract][Full Text] [Related]
29. Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds. Kreitman RJ; Batra JK; Seetharam S; Chaudhary VK; FitzGerald DJ; Pastan I Bioconjug Chem; 1993; 4(2):112-20. PubMed ID: 7873642 [TBL] [Abstract][Full Text] [Related]
30. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model. Kreitman RJ; Chang CN; Hudson DV; Queen C; Bailon P; Pastan I Int J Cancer; 1994 Jun; 57(6):856-64. PubMed ID: 8206679 [TBL] [Abstract][Full Text] [Related]
31. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. Onda M; Nagata S; FitzGerald DJ; Beers R; Fisher RJ; Vincent JJ; Lee B; Nakamura M; Hwang J; Kreitman RJ; Hassan R; Pastan I J Immunol; 2006 Dec; 177(12):8822-34. PubMed ID: 17142785 [TBL] [Abstract][Full Text] [Related]
32. Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivatization. Benhar I; Brinkmann U; Webber KO; Pastan I Bioconjug Chem; 1994; 5(4):321-6. PubMed ID: 7948099 [TBL] [Abstract][Full Text] [Related]
33. Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice. Reiter Y; Wright AF; Tonge DW; Pastan I Int J Cancer; 1996 Jul; 67(1):113-23. PubMed ID: 8690511 [TBL] [Abstract][Full Text] [Related]
34. Recombinant single-chain immunotoxins against T and B cell leukemias. Kreitman RJ; Pastan I Leuk Lymphoma; 1994 Mar; 13(1-2):1-10. PubMed ID: 8025511 [TBL] [Abstract][Full Text] [Related]
35. Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity. Theuer CP; Kreitman RJ; FitzGerald DJ; Pastan I Cancer Res; 1993 Jan; 53(2):340-7. PubMed ID: 8417828 [TBL] [Abstract][Full Text] [Related]
36. An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxin. Debinski W; Pastan I Bioconjug Chem; 1994; 5(1):40-6. PubMed ID: 8199233 [TBL] [Abstract][Full Text] [Related]
37. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. Reiter Y; Brinkmann U; Jung SH; Lee B; Kasprzyk PG; King CR; Pastan I J Biol Chem; 1994 Jul; 269(28):18327-31. PubMed ID: 7913461 [TBL] [Abstract][Full Text] [Related]
38. Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv. Chowdhury PS; Vasmatzis G; Beers R; Lee B; Pastan I J Mol Biol; 1998 Sep; 281(5):917-28. PubMed ID: 9719644 [TBL] [Abstract][Full Text] [Related]